 Hoth Therapeutics Inc NASDAQ: HOTH has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia. 